Supplementary materials for A Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis
Published: 20 November 2024| Version 3 | DOI: 10.17632/w2vksw3xdd.3
Contributor:
Description
Supplementary tables
Files
Institutions
Zhejiang University
Categories
Word Production